Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of Trigonella foenum-graecum extract on prostate-specific antigen, and prostate function in otherwise healthy men with benign prostate hyperplasia.
|
31828857 |
2020 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As BPH-related factors, International Prostate Symptom Score, quality of life, maximal flow rate, postvoid residual volume, prostate-specific antigen, prostate volume, prostate calculi, and medication state for BPH were investigated.
|
31734054 |
2020 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The control group consisted of 28 men under long-term follow-up (mean of 8.7 ± 3.0 years) for benign prostate hyperplasia (BPH), with persistently elevated PSA (above 4 ng/mL) and several prostate biopsies negative for cancer (mean of 2.7 ± 1.3 biopsies per control).
|
31808398 |
2020 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the protein expressions of AR, 5AR2, and PSA were significantly lower in the PE gavaged group than BPH group in prostate tissue.
|
31591335 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels.
|
31534967 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals.
|
31569672 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rats with BPH exhibited outstanding BPH manifestations, including prostate enlargement, histological alterations, and increased prostate-specific antigen (PSA) levels.
|
31547405 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, PSA is the only PCa biomarker applied clinically, but it does not perform well in the early diagnosis and distinguishing between benign prostatic hyperplasia and prostate cancer.
|
31421692 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As a result of analysis using sera from 15 PCa or 15 benign prostate hyperplasia (BPH) patients whose PSA levels were in the "gray zone" (4.0-10.0 ng/mL), 52 glycan structures on PSA were quantitatively observed.
|
30669833 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, PSA, apolipoprotein B, fasting blood glucose, cholesterol, HDL, and low-density lipoprotein (LDL) levels were predictors of BPH/LUTS at the initial health examination.
|
31626149 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of GG, AG, and AA genotypes of KLK3 polymorphism was 24.6% and 76.2%, 46.6% and 21.7%, and 28.8% and 2.1%, in patients with BPH and PC, respectively (P < 0.001).
|
31017705 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Correlation analyses suggested up-regulation of prostatic ARF6 expression with increasing degree of BPH, as ARF6 expression increased with the content of prostate-specific antigen (PSA) of prostate tissues.
|
31243101 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
When PSA is moderately increased (e.g., 4-10 ng/ml), it is difficult to differentiate benign prostatic hyperplasia (BPH) from cancer.
|
30610587 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A previously developed liquid chromatography-mass spectrometry/mass spectrometry-based strategy was used for multiplex analysis of core-fucosylated prostate-specific antigen (fuc-PSA) and total prostate-specific antigen levels in sera from 50 benign prostate hyperplasia and 100 prostate cancer patients of different aggressiveness (Gleason scores, 5-10) covering the critical gray area (2-10 ng/mL).
|
30907281 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since PSA is expressed exclusively by prostatic luminal epithelial cells, PSA in the BPH stroma suggests increased tissue permeability and the compromise of epithelial barrier integrity.
|
31212363 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of TE and PSA, and prostate weight (PW) were significantly increased in BPH group and significantly decreased in curative and preventive ones.
|
31263839 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was also found that diosmin downregulated the expression of androgen receptor and decreased the prostate-specific antigen concentration dose-dependently, significantly against TP-induced BPH.
|
31797688 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we described an Italian pedigree affected by HHL but also prostate hyperplasia and increased ratio of the free/total PSA levels, with the unusual and extremely rare Y-linked pattern of inheritance.
|
30341416 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the PSA levels were correlated with the expression of DRD1 in BPH cases and DRD1, DRD4, DRD5, and IL6 in PCa cases.
|
31288722 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Then, LCW was treated with BPH-1, a human BPH cell line, at 25, 50, 100 μg/mL for 24 h and examine mRNA level of androgen receptor (AR) and prostate-specific antigen (PSA).
|
30724641 |
2019 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently prostate-specific antigen is used for prostate cancer (PCa) screening, however it lacks the necessary specificity for differentiating PCa from other diseases of the prostate such as benign prostatic hyperplasia (BPH), presenting a clinical need to distinguish these cases at the molecular level.
|
29695737 |
2018 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, <i>p</i> < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm<sup>3</sup>, <i>p</i> = 0.02).
|
30186533 |
2018 |
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that patients with incidental prostate cancer who have both prostate-specific antigen density ≤0.08 after benign prostatic hyperplasia surgery as well as invisible cancer lesion on multiparametric magnetic resonance imaging should be considered for active surveillance.
|
30592769 |
2018 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STK1 concentration and total PSA were significantly higher in patients with prostate carcinoma compared with patients with BPH and healthy individuals.
|
30333882 |
2018 |
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |